Underwriters' over-allotment will be up to an additional 500K shares.
The Rehovet, Israel-based biopharmaceutical outfit develops treatments for rare and aggressive cancers by leveraging its bioinformatics platform and next-gen sequencing.
https://www.ayalapharma.com/
No comments:
Post a Comment